Prognostic significance of [18F]fluorodeoxyglucose uptake on positron emission tomography in patients with pathologic stage I lung adenocarcinoma

[18F]Fluoro‐2‐deoxyglucose uptake on positron emission tomography (FDG‐PET) has been frequently used for diagnosis and staging of lung cancer. The prognostic significance of FDG uptake on PET was evaluated in patients with pathologic Stage I lung adenocarcinoma (tumor stages were based on the TNM classification of the International Union Against Cancer).

[1]  T. Naruke,et al.  [F-18]Fluorodeoxyglucose positron emission tomography can predict pathological tumor stage and proliferative activity determined by Ki-67 in clinical stage IA lung adenocarcinomas. , 2006, Japanese journal of clinical oncology.

[2]  R. Cerfolio,et al.  The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival. , 2005, The Journal of thoracic and cardiovascular surgery.

[3]  M. Rabin,et al.  Patient Subsets Benefiting from Adjuvant Therapy Following Surgical Resection of Non–Small Cell Lung Cancer , 2005, Clinical Cancer Research.

[4]  Robert Livingston,et al.  Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. , 2005, The New England journal of medicine.

[5]  T. Naruke,et al.  Fluorine 18-tagged fluorodeoxyglucose positron emission tomographic scanning to predict lymph node metastasis, invasiveness, or both, in clinical T1 N0 M0 lung adenocarcinoma. , 2004, The Journal of thoracic and cardiovascular surgery.

[6]  T. Naruke,et al.  Evaluation of F-18 fluorodeoxyglucose (FDG) PET scanning for pulmonary nodules less than 3 cm in diameter, with special reference to the CT images. , 2004, Lung cancer.

[7]  T. Naruke,et al.  Is major pulmonary resection by video-assisted thoracic surgery an adequate procedure in clinical stage I lung cancer? , 2004, Chest.

[8]  H. Kato,et al.  A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. , 2004, The New England journal of medicine.

[9]  J. Herndon,et al.  T1 lung cancers: sensitivity of diagnosis with fluorodeoxyglucose PET. , 2002, Radiology.

[10]  P. Dupont,et al.  Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: An analysis of 125 cases. Leuven Lung Cancer Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  D. Carter.  TNM Classification of Malignant Tumors , 1998 .

[12]  S. Hirohashi,et al.  Small adenocarcinoma of the lung. Histologic characteristics and prognosis , 1995, Cancer.

[13]  E. Bergstralh,et al.  Postsurgical stage I bronchogenic carcinoma: morbid implications of recurrent disease. , 1984, The Annals of thoracic surgery.

[14]  T. Naruke,et al.  Fluorodeoxyglucose Positron Emission Tomography Can Predict Pathological Tumor Stage and Proliferative Activity Determined by Ki-67 in Clinical Stage IA Lung Adenocarcinomas , 2006 .

[15]  M. Sagawa,et al.  Fluorodeoxyglucose Uptake Correlates with the Growth Pattern of Small Peripheral Pulmonary Adenocarcinoma , 2005, Surgery Today.

[16]  W. Kuschner,et al.  Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. , 2001, JAMA.

[17]  D.,et al.  Regression Models and Life-Tables , 2022 .